Fulltext:
196413.pdf
Embargo:
until further notice
Size:
353.3Kb
Format:
PDF
Description:
Publisher’s version
Publication year
2018Source
Current Opinion in Lipidology, 29, 5, (2018), pp. 359-367ISSN
Publication type
Article / Letter to editor
Display more detailsDisplay less details
Organization
Internal Medicine
Journal title
Current Opinion in Lipidology
Volume
vol. 29
Issue
iss. 5
Page start
p. 359
Page end
p. 367
Subject
Radboudumc 16: Vascular damage RIMLS: Radboud Institute for Molecular Life Sciences; Radboudumc 6: Metabolic Disorders RIMLS: Radboud Institute for Molecular Life Sciences; Internal Medicine - Radboud University Medical CenterAbstract
PURPOSE OF REVIEW: It is increasingly recognized that profound metabolic changes occur in activated myeloid cells, which shape their inflammatory phenotype and cellular functions. The purpose of this review is to summarize the accumulating evidence that major metabolic adaptations occur in monocytes and macrophages in the context of atherosclerosis ultimately modulating atherosclerotic plaque formation. RECENT FINDINGS: Plaque macrophages show a profound metabolic reprogramming which is driven by atherogenic factors in the plaque microenvironment, such as damage associated molecular patterns, modified lipoproteins, and hypoxia. In addition, systemic atherogenic factors modulate metabolism of circulating monocytes and their bone marrow progenitors. Activation of glycolysis, the pentose phosphate pathway, and fatty acid synthesis, a reduction of fatty acid oxidation accompanied by complex changes in the lysosomal handling of lipids all appear to facilitate atherogenesis. These processes also drive the development of trained immunity, a phenomenon describing the persistent pro-inflammatory phenotype that develops after brief stimulation of monocytes with pro-atherogenic stimuli. SUMMARY: A pro-atherosclerotic environment reprograms the metabolism of myeloid cells in the various developmental phases of atherosclerosis. Knowledge of these metabolic programs facilitates the development of novel drugs to prevent atherosclerotic cardiovascular disease.
This item appears in the following Collection(s)
- Academic publications [248380]
- Electronic publications [135674]
- Faculty of Medical Sciences [94201]
Upload full text
Use your RU or RadboudUMC credentials to log in with SURFconext to upload a file for processing by the repository team.